Bharat Biotech on Tuesday said it has ramped up the manufacturing capacity of its COVID-19 vaccine Covaxin to 70 crore doses annually amid a record surge in cases in India. This comes after the government approved over ₹1,500 crore in advance payment to the company. Last week, the Centre also authorised a ₹65 crore grant for Bharat Biotech's Bengaluru facility.